IN-DATE
06G-300-014: CSI Zilient 6g Peripheral Guidewire 0.014" x 300cm
Sign in to add this product to your favorites!
| Price: | $293.00 per box of 5 |
|---|---|
| Quantity: | |
| In Stock: | 1 box of 5 |
| Status: | expired |
Additional Details
Abbott CSI Zilient Peripheral Guidewire
- One-Piece Core Wire provides exceptional torque response and reliable support from proximal end to distal tip.
- Hydrophilic Coating provides superior lubricity for calcified or highly-stenosed lesions.
- Proprietary Twister® for improved navigation and torque control even in prolonged procedures.
AccessGUDID Info
- FDA Product Code: MCW
- FDA Product Code Name: Catheter, Peripheral, Atherectomy
- GMDN Term Code: 58115
- GMDN Term Name: Peripheral vascular guidewire, manual
- GMDN Term Description: A long, thin wire intended to be percutaneously placed into the peripheral vasculature (not heart or central nervous system) to function as a guide for the introduction of devices (e.g., catheters). It is made of metal (e.g., stainless steel, Nitinol), with or without coating, and is available in a variety of distal tip designs. It is intended to be used for percutaneous angiography, angioplasty, rotational atherectomy and thrombectomy, drainage, and other diagnostic and interventional procedures. It may include devices used to facilitate manipulation (e.g., torque device). This is a single-use device.
Manufacturer
Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.
